An independent reading of one investigational molecule

What this site is

Retatrutide Prescribed is an independent editorial project that publishes summaries of the peer-reviewed research literature on retatrutide. The format is a small bound reading room — five reading pages and a reference list — written carefully, sourced primarily, and updated when new published evidence merits the work.

The publisher is not a clinic. We do not employ clinicians, and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

What the domain name does not mean

The word 'prescribed' in this site's domain name is editorial framing — a position the publisher occupies relative to the literature. It signals that the page reads the molecule as if it were already a prescriptive object in the medical conversation: a thing one could imagine being prescribed, and which therefore deserves the same kind of careful editorial reading that any prescribable molecule would.

It is not a claim that this site provides prescriptions. It is not a referral to a prescribing service. Retatrutide cannot be prescribed in any jurisdiction today, by any clinician, through any pharmacy. The site is a reading room, not a clinic, and not a route to a clinic.

How the writing is sourced

Every quantitative claim on this site is grounded in a primary publication, a registered clinical-trial record, or a sponsor topline disclosure (clearly labeled as such). The bibliography lives on /references with full citation metadata, DOIs where available, and links to PubMed, ClinicalTrials.gov, or the journal of record.

Secondary sources — news coverage of conference presentations, for example — are used only where the underlying primary publication is not yet available, and are labeled as such. We do not cite forum posts, vendor marketing, or anonymous web content. When the published trial record does not yet answer a question, the site says so explicitly.

Editorial standards

The voice is clinical-but-approachable: precise on the science, plain on the language, calm on the uncertainty. We try not to overstate, but we also try not to write timidly. Where the trials report a number, we report that number with its source. Where the trials are silent, we name the silence.

We do not name brand-marketed competitor products by their brand names. The relevant comparator molecules in the broader incretin field are referred to by their International Nonproprietary Names (the generic compound names) only.

We do not write prescriptive language. The verb 'should' is reserved for descriptions of what published authors recommend, never for instruction to readers.

Affiliation and conflicts

This reading room is not affiliated with Eli Lilly, the sponsor of retatrutide's clinical development program. It is not affiliated with any other pharmaceutical manufacturer, compounding pharmacy, telehealth provider, research-chemical vendor, or patient-recruitment organization. No payment, free product, or any form of consideration is accepted from any commercial party named in our coverage.

This is an independent editorial project. It does not manufacture, sell, or distribute any product and carries no commercial relationship with any vendor or manufacturer in this space. The footer disclaimer on every page is the contract.

A small note from the editor

Most of what gets written publicly about investigational molecules either reads as a press release or as the comment section of a press release. Neither serves the reader. The small ambition here is to put one molecule on a quiet shelf, read its trial record carefully, and leave the page in a state where a curious reader can pick it up and learn something genuine before deciding what to do with the information.

If there is an error of fact, or a published result we have missed, /contact is the place to write.